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Abstract
A “reverse pharmacology” approach to developing an anti-malarial phytomedicine was designed and implemented
in Mali, resulting in a new standardized herbal anti-malarial after six years of research. The first step was to select a
remedy for development, through a retrospective treatment-outcome study. The second step was a dose-
escalating clinical trial that showed a dose-response phenomenon and helped select the safest and most
efficacious dose. The third step was a randomized controlled trial to compare the phytomedicine to the standard
first-line treatment. The last step was to identify active compounds which can be used as markers for
standardization and quality control. This example of “reverse pharmacology” shows that a standardized
phytomedicine can be developed faster and more cheaply than conventional drugs. Even if both approaches are
not fully comparable, their efficiency in terms of public health and their complementarity should be thoroughly
considered.
Background
Malaria elimination efforts will lead to the much wider use
of the few currently effective anti-malarial drugs, such as
artesunate / amodiaquine, artesunate / sulphadoxine-
pyrimethamine (SP), and artemether / lumefantrine. There
is already discussion about intermittent presumptive treat-
ment of infants, children, pregnant women, and even mass
drug administration in some settings [1]. Resistance
already exists to amodiaquine and SP, and will probably
increase as a result of the increased drug pressure. The
first signs of resistance to artemisinin derivatives are
appearing in Cambodia [2].
In this context it is important to maximize the life-
span of existing anti-malarials, and to consider all
options for the development of new anti-malarials. Tra-
ditional medicinal plants have provided the source of
the two major families of anti-malarial drugs still in use
today, artemisinin and quinine, so many researchers are
screening plants for novel chemical entities to develop
as “lead compounds” for new anti-malarial drugs [3].
However conventional drug development is slow and
expensive, taking up to 15 years and up to $800m to
develop a new drug [4,5]. Furthermore the finished pro-
ducts are often unavailable and unaffordable to the
poorest patients in remote areas, unless they are part of
a heavily subsidized scheme.
In contrast the parallel development of standardized
phytomedicines can be done faster, more cheaply, and
more sustainably for remote areas. They could then be
proposed and tested as a complement to existing strate-
gies, for example as first aid in remote areas in case
there is some delay until ACT treatment can be started.
Their use might also delay the development of resis-
tance to current standard drugs. The concept of “reverse
pharmacology” was coined in India to develop pharma-
ceuticals from Ayurvedic medicines, and was also cham-
pioned by the Chinese in the 1950s [6], but still
involved a classical pathway of isolating compounds for
further development [7]. The saving in time and cost
comes from the fact that substantial experience of
human use increases the chances that a remedy will be
effective and safe, and that precautions will be known.
However, as with classic drug discovery, there is no
guarantee of successfully developing new treatments.
In order to develop a standardized phytomedicine, a
“reverse pharmacology” approach was tested, where clin-
ical evaluation was prioritized from the start. Isolation of
compounds was done only at the end of the pathway,
mainly for the purposes of quality control, agronomic
selection and standardization, if justified by the clinical
results. This experience led to the development of a new
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remedy, namely Argemone mexicana decoction, which is
in the process of being approved in Mali. The regulatory
requirements for herbal medicines are completely differ-
ent to those for new drugs. It should be emphasized
that the primary objective of the project described here
was not to develop new drugs, but to improve the utili-
zation of herbal medicines, which are already in use. All
the clinical studies described below were reviewed and
approved by the Ethics Committee of the Institut
National de Recherche en Santé Publique (INRSP) in
Mali. This process took six years and cost about 400,000
Euros.
The research project is described here as it actually
happened. Some aspects are reviewed in the discussion
section, as with the benefit of hindsight some proce-
dures might be improved. The hope is that this paper
may help others who are interested in conducting a
similar process (developing phytomedicines, perhaps for
other indications) through a clear report of what was
planned, what was opportunistically added – and what
was obtained.
Stage 1: Selection of a herbal remedy
The classical way of identifying medicinal plants for
further research is through ethnobotanical studies. Yet
conventional ethnobotanical studies rarely involve clini-
cians. They could and should provide much more clini-
cal information if the ultimate goal is to know which
one, among numerous treatments for a given ailment,
has the best effects [8]. Although identification of the
plants is usually of a good standard, definition of the
diseases which they treat is not. There is rarely sufficient
questioning about the observed patient status and pro-
gress, perceived efficacy and limitations of the remedies,
and whether these are indeed the “treatment of choice”.
Many plants are “supposed” to be good for one disease
or another, but are not actually the preferred treatment
used in everyday life. In order to circumvent these pro-
blems, Graz et al developed a new method called a “Ret-
rospective Treatment Outcome Study” (RTO) [9]. This
simply adds two essential elements to the ethnobotanical
method: clinical information and statistical analysis.
Clinical information is collected retrospectively on the
presentation and progress of a defined disease episode.
Treatments and subsequent clinical outcomes are ana-
lysed to elicit statistically significant correlations
between them. Such an approach requires a large sam-
ple if the number of different treatments is high. This
method makes it possible to identify the remedy which
has the highest statistical correlation with reported clini-
cal recovery. The hypothesis is that this correlation is a
marker of effectiveness, which can then be further tested
in a prospective clinical study of the selected remedy.
It was also hypothesized that if a treatment is often asso-
ciated with failure, this is a marker of ineffectiveness.
In the RTO, the first step was to understand local
concepts and terms for diseases. The aim was to maxi-
mize the chances that the respondents were giving
information about the disease of interest to researchers.
For uncomplicated malaria, the definition was “fever
with no other obvious cause during the rainy season”
and for severe malaria, it was “fever with convulsions or
loss of consciousness during the rainy season” [10]. In
Mali, these correspond to the local Bambara terms “sou-
maya” and “kono” respectively. Of course these are not
very precise, but they are the same definitions as those
used for presumptive treatment [11], and the best that
can be done retrospectively, when blood tests are
impossible.
The second step was to choose a representative ran-
d o ms a m p l eo fh o u s e h o l d si nt h es t u d ya r e a( b yc l u s t e r
sampling), and to ask in each whether anyone has had
the disease of interest in the recent past. The timing
was at the end of the malaria season (for example in
Mali the rains begin in July and the perfect time for
such a study would be in November - December). For
uncomplicated malaria, a recall time of two weeks was
used (as this is a common event, and there is a risk that
information will be inaccurate if the recall period is too
long) [10]. For severe malaria (which is rarer and more
dramatic, so more likely to be remembered) a recall per-
iod of six months was used. The sample size was deter-
mined on the basis of the estimated prevalence of
malaria in the area, and the estimated number of differ-
ent treatments (from previous information).
The third step, if a respondent had had the condition
of interest, was to ask in detail what treatments they
had taken, in what order, at what stage they had recov-
ered from their illness and if the cure was complete or
with sequelae. In this way it was possible to understand
what treatments patients were actually using in real life
and with what results.
In Mali, use of this method resulted in a database of
treatments taken for malaria cases in 952 households.
The analysis was an iterative process performed with the
help of a statistician, starting with a test of correlation
between reported clinical outcome and the plant used.
Since in some cases recipes contained more than one
plant, a second step was to adjust for this in the analysis,
in an attempt to determine whether individual compo-
nents were associated with clinical outcomes. From the
66 plants used for the treatment of malaria in the two
districts studied in Mali, alone or in various combina-
tions, the one associated with the best outcomes was a
decoction of Argemone mexicana (Table 1). The clinical
outcomes were not better when it was used in combina-
tion [12]. This remedy was selected for further study.
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of the plants for their anti-malarial activity in vitro
(Table 2). Argemone mexicana had the best activity
in vitro, both for the extracts in polar solvents and the
aqueous decoction [12] The IC50 of the methanol
extract was 1.0 μg/ml, which is of the same order as the
ethanolic extract of Artemisia annua[13].
Before proceeding to clinical studies, it is important to
establish that the remedy is safe. WHO guidelines [14]
state that: “If the product has been traditionally used
without demonstrated harm, no specific restrictive regu-
latory action should be undertaken unless new evidence
demands a revised risk-benefit assessment.” WHO main-
tains the position that there is no requirement for
pre-clinical toxicity testing; rather that evidence of tradi-
tional use or recent clinical experience is sufficient [15].
Indeed often the same plants are traditionally used both
as a food and as a medicine [16], and no toxicological
tests are required for foods, which are usually consumed
in greater quantities than medicines. Pre-clinical toxicity
testing is only required for new medicinal herbal pro-
ducts which contain herbs with no traditional history of
use. Therefore, if preliminary field studies (such as the
RTO study) have shown that the preparation is of com-
mon and ancient use, with no known important side
effects, toxicological studies are unnecessary [17].
The literature was searched extensively [18] to see
whether the safety of the remedy had already been
established in previous studies. The aim was to find stu-
dies of the same plant part, using a similar extraction
method, to answer the following questions:
1. Are there any reports of human toxicity associated
with ingestion of the plant? If so, which part of the
plant, in what preparation, at what dose, and what were
the consequences?
2. Have any laboratory studies of toxicity been carried
out on the relevant preparation of the plant? If so, what
did the results show?
3. What pharmacologically active compounds does
this plant species contain? In which parts of the plant
are they found? What are their principle pharmacologi-
cal effects, and at what doses?
Search terms included the plant species and major
chemical compounds known to exist in the plant
Table 1 Sample results from the RTO study for the three most promising plants (the full table included 66 plants in
total)
Plant Preparation No of cases
reporting use
No of cases reporting
clinical recovery
No of
treatment
failures
Correlation with
clinical recovery
(95% CI) P (Fisher)
*
Argemone mexicana
(Papaveraceae)
Aerial parts
decoction
30 30 0 100% (88-100) NA (best
results)
Carica papaya Leaves
decoction
33 28 5 85% (68-95) 0.05
Anogeissus leiocarpus Leaves 33 27 6 82% (64-93) 0.03
*(Number with and without clinical recovery compared to the plant with best results.
Table 2 In vitro anti-malarial activity of plant extracts identified in a retrospective treatment-outcome study, for
plants with aqueous extracts having IC50 <10 μg/ml [12]
Plant Plant part Extract IC50 (μg/ml)
Argemone mexicana Aerial parts Methanol 1.00
Argemone mexicana Aerial parts Dichloromethane 1.22
Argemone mexicana Aerial parts Aqueous decoction 5.89
Argemone mexicana Aerial parts Aqueous maceration 6.22
Opilia celtidifolia Bark Aqueous maceration 7.64
Spondias mombin Leaves Aqueous maceration 7.66
Securinega virosa Leaves Aqueous decoction 7.81
Spondias mombin Leaves Aqueous decoction 7.89
Cassia sieberiana Roots Aqueous maceration 7.93
Canthium acutiflorum Leaves Aqueous maceration 8.09
Securinega virosa Roots Aqueous decoction 8.69
Opilia celtidifolia Bark Maceration in warm water then decoction 9.07
Feretia apodanthera Bark Aqueous decoction 9.54
Securinega virosa Roots Aqueous maceration 9.68
Canthium acutiflorum Bark Aqueous decoction 9.73
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the existing databases or books can cover all published
i n f o r m a t i o no nag i v e nt o p i c ,a n dt h e r e f o r ea sm a n y
sources of information as possible were consulted: firstly
freely available online databases [19,20]; then reference
books such as pharmacopoeiae and similar monographs
[21], and texts on plant toxicology and herbal medicine
safety [22-24]; and finally, other databases: EMBASE,
CAB Global Health, and the Allied and Complementary
Medicine database.
In the case of Argemone mexicana, the literature
search revealed no toxicology studies but there were
reports of “epidemic dropsy” in India attributed to the
ingestion of the seed oil containing sanguinarine, as a
contaminant in culinary oils [25]. This was of some con-
cern, therefore the traditional healer was asked to
remove seed capsules from the preparation used for
clinical studies in Mali. However, there were no refer-
ences to toxicity from an aqueous decoction of the
leaves and stems (which was the traditional preparation
in question), and this remedy was reported in the ethno-
botanical literature as being used in Benin, Mali, India
and Colombia [26-29].
Stage 2: Dose-escalating clinical study
As patients were using the remedy in any case, and the
literature search did not reveal any concerns, an obser-
vational cinical study was organized with a small num-
ber of patients. It is a prerequisite to conduct such a
study in an area where patients are already taking the
remedy, so that one is not proposing a new treatment
(for example for a comparative prospective study – see
below) without some clinical evidence of effect size and
safety.
The traditional preparation was given to patients with
uncomplicated malaria, who met the following criteria:
1. Inclusion criteria:
a. Symptoms of malaria (fever) within the last 24 hours
b. Parasitaemia >2000/mcl and <200 000 / mcl on
microscopy
c. Informed consent of patient or parent
2. Exclusion criteria:
a. Signs of severe malaria
b. age <3 months
c. pregnancy
d. other concomitant febrile illness
e. administration of a full course of anti-malarial
(modern or traditional) within the previous week
f. inability to return for follow-up.
Patients were followed up closely on days 1, 2, 3, 7, 14
and 28, and were advised to return immediately at any
other time if their condition deteriorated. Monitoring
included parameters of efficacy (temperature, symptoms,
parasite counts) and safety (new symptoms/adverse
events, ECGs, and blood tests to monitor bone marrow
function, renal function and liver function). The design
of the whole study became a sequential follow-up of
patients using, in the first group, a dose lower than the
one traditionally used (but, at the time, proposed as the
correct one by the traditional healer), then the bottom
a n dt o po ft h eu s u a ld o s er a n g e( s e eF i g u r e1 ) .I nt h i s
way patients always received the best dose according to
the current state of knowledge. If the incidence of
important adverse effects reached an unacceptable level,
t h et r i a lc o u l do fc o u r s eb es t o p p e d .C o m p l i a n c ew a s
monitored by direct observation of some doses of the
treatment (the first dose of each of the first three days
when the patient attended for follow-up) and by asking
patients whether they had taken the recommended
dosage during the rest of the day. Thus, it was also pos-
sible to assess whether the optimal dosage was realistic
and feasible in the field.
The outcome measures chosen were appropriate to
the context in which use of the phytomedicine was envi-
saged, which was a high-transmission area (Tables 3 and
4). In low transmission areas, the outcome recom-
mended by WHO is “Adequate Clinical and Parasitolo-
gical Response” (ACPR) which includes a requirement
that the parasite count by day 3 is reduced to <25% of
baseline, and that total parasite clearance is achieved by
day 7 and maintained through to day 28 [30]. Although
WHO now also recommends total parasite clearance in
all situations, this may not be necessary in high trans-
mission areas where the population develops partial
immunity in early life, and is rapidly re-infected even if
parasite clearance is achieved. In such high transmission
areas, the most useful outcome measures are clinical
rather than parasitological. One such is the rate of “ade-
quate clinical response” (ACR, see table 3), which is a
modification of ACPR. The criterion that parasitaemia
on day 3 should have decreased to <25% of that on day
0 was designed for fast-acting drugs, such as chloro-
quine and artemisinin derivatives. It is not an essential
criterion for testing slower-acting drugs, such as quinine
and herbal remedies, and therefore can be omitted for
such trials [31]. If patients clinically worsened or did not
recover (i.e. “treatment failures”)t h e yw e r eg i v e na n
alternative treatment (the nationally recommended anti-
malarial).
The idea of dose escalation was developed by chance.
T h eo r i g i n a li n t e n t i o nw a st oo b s e r v eac o h o r to f
patients being treated by a traditional healer at a dose
decided by the healer. However, it soon became clear
that the dose initially chosen by the healer (“A” =o n e
glass a day for 3 days) was insufficient, with an ACR in
only 35% of patients. When questioned why he had cho-
sen this dose, the healer replied that he thought it was
“more scientific” (perhaps because it is similar to the
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t h r e ed a y s ) .H et h e nr e v e a l e dt h a ti nf a c th en o r m a l l y
told patients how to prepare the remedy, and advised
them to drink as much of it as possible. Therefore two
other standard doses were agreed: one glass twice a day
for 7 days (B), and one glass 4 times a day for the first
4 days, followed by one glass twice a day up to 7 days
(C). Increasing the dose from A to B improved the effi-
cacy (the proportion of patients with ACR increased
from 35% to 73%) without an increase in adverse effects.
However, at the maximal dose, there was no additional
benefit (ACR in 65%), and two patients developed a pro-
longed QTc interval on their ECG. Thus an intermedi-
ate dose (B) was chosen as the safest and most effective
to take forward into the next stage [32].
A voucher specimen of the plant harvested for making
the phytomedicine was deposited in the herbarium of
the Department for Traditional Medicine. Thin-layer
chromatography of the plant extract (methanol) and of
the decoction was used to identify already published
Rangeoftraditionallyrecommended
doses:
Startwithlowestdose
Clinicalresults
Insufficient
effectiveness
Goodeffectiveness
Safeandwelltolerated Safeandwelltolerated
NO NO YES YES
Decreasedose Increasedose
Stop the trial 
(failure) 
Optimaldose
Figure 1 Dose optimization.
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confirmed by HPLC and mass spectroscopy. Berberine
and sanguinarine were detected in the methanol extract
but sanguinarine was not detectable in the decoction. Lyo-
philized samples of the phytomedicine used were kept for
reference, and future phytochemical fingerprinting.
Although according to WHO guidelines it would not
have been necessary, the opportunity arose to conduct
toxicological studies. These were conducted in parallel
with the dose-escalating clinical trial. The LD50 of the
freeze-dried decoction of the aerial parts was deter-
mined twice in two different laboratories which both
showed that it was >3000mg/kg, as no rats or mice were
adversely affected even by this high dose [33,34]. There
is always a concern that some toxic ingredients are not
absorbed in rodent species, but this was reassuring in
the context of a long history of use of the leaf decoction
in humans, with no reported toxicity.
Stage 2: 
Dose-escalating clinical trial 
x Increase dose sequentially 
x Observe clinical effects 
x Assess safety 
x Choose optimal dose 
Stage 3: 
Randomized controlled trial 
x Pragmatic inclusion criteria and outcomes 
x Compare to standard first-line drug  
x Test effectiveness in the field 
Stage 4: 
Isolation of active compounds 
x In vitro antiplasmodial tests of 
purified fractions and isolated 
compounds from the decoction 
x To permit standardization and quality 
control of phytomedicine 
x For agronomic selection 
x For pharmaceutical development 
Stage 1:
Selection of a remedy 
x Retrospective Treatment Outcome Study 
x Literature review (selected remedy) 
Figure 2 Summary of the methodology used to develop an anti-malarial phytomedicine by “reverse pharmacology”.
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As results from all previous stages were encouraging,
the aim at this stage was to test the effectiveness of the
phytomedicine in the field. In Mali, the objective was to
develop a phytomedicine for home-based management
of malaria (HMM), with the aims of symptomatic
improvement and preventing severe malaria. The vision
was that, if effective, the plant could be recommended
to communities to be cultivated and prepared locally as
a first-line treatment for presumed malaria. Therefore,
the inclusion criteria for the RCT reflected this: all
patients with presumed malaria (history of fever during
the last 24 hours, without another obvious cause, during
the rainy season) were included.
It is not ethical to give placebo or no treatment to the
control group, because falciparum malaria is potentially
fatal and can progress rapidly, particularly in non-
immune patients. The most useful comparator is the
nationally recommended first-line treatment. In most
countries this is now an artemisinin combination ther-
apy (ACT). In Mali it was artesunate-amodiaquine.
Artemisinins are the most effective and rapid anti-
malarial drugs ever discovered, so it is not realistic to
aim for a herbal treatment to outperform an ACT.
Rather the aim should be non-inferiority for the selected
appropriate outcome measures, or at least reaching a
certain pre-defined level of effectiveness.
The outcome measures are summarized in table 4 and
the results in table 5. The primary outcome measure
was “clinical recovery” at day 28, without the need for a
second-line treatment. Over 28 days, second-line treat-
ment was not required for 89% (95% CI 84.1–93.2) of
patients on A. mexicana, versus 95% (95% CI 88.8–98.3)
on artesunate-amodiaquine. An important secondary
outcome measure was incidence of severe malaria,
which is the most important outcome in public health
terms. Large numbers of patients are needed in order to
demonstrate non-inferiority, because severe malaria is a
relatively uncommon event. However another approach
is to see whether the incidence of severe malaria is kept
below a pre-specified level in both groups [35]. In a pre-
vious study in a similar context, age-specific incidence
(age <5 years) of severe malaria in untreated patients
with presumed malaria was about 11%, and in patients
treated at home with chloroquine (the standard treat-
ment at that time) was about 5% per month [36]. The
aim was, therefore, to keep the age-specific incidence of
severe malaria (in patients aged <5 years) below 10%,
and ideally ≤5%, in both groups. A sample of 300
patients was needed to answer this question (100
patients treated with ACT and 200 with A. mexicana
decoction); an unequal randomization ratio was chosen
in order to collect, with equal means, more information
on the less known treatment. The observed age-specific
incidence of severe malaria (in children aged 0-5 years)
Table 3 Modified classification of treatment outcomes for
trials on herbal antimalarials in high transmission areas
[31,43]
Adequate Clinical Response(ACR)
On day 14, without previously meeting any of the criteria of Early
Treatment Failure or Late Treatment Failure:
￿ Either absence of parasitaemia irrespective of axillary temperature
￿ Or axillary temperature <37.5°C and no history of fever in the last
24 hours irrespective of the presence of parasitaemia
Early Treatment Failure(ETF)
￿ Development of danger signs or severe malaria on Day 1, Day 2 or
Day 3, in the presence of parasitaemia;
￿ Parasitaemia on Day 2 higher than Day 0 count irrespective of
axillary temperature;
￿ Parasitaemia on Day 3 with axillary temperature ≥ 37.5 °C;
afebrile patients with parasitaemia on day 3 ≥25% of count on day 0
will NOT be counted as early treatment failures, but will be observed
closely
Late Treatment Failure(LTF)
￿ Development of danger signs or severe malaria after Day 3 in the
presence of parasitaemia, without previously meeting any of the
criteria of Early Treatment Failure
￿ Presence of parasitaemia and axillary temperature ≥ 37.5 °C (or
history of fever) on any day from Day 4 to Day 14, without
previously meeting any of the criteria of Early Treatment Failure
Table 4 Outcome measures used in a high-transmission area
Study Primary Outcome Secondary outcomes
Observational study: Dose-escalating
clinical trial
% of patients with Adequate Clinical Response at d14 in
each dosage group (= dose response)
% of patients with Adequate Clinical Response
at d28
% of patients with total parasite clearance at
days 14 and 28
% of patients experiencing adverse effects
Experimental study: Pragmatic
Randomized Controlled Trial
‘clinical recovery’ at day 28 without need for re-treatment
with the second-line anti-malarial
Axillary temperature <37.5’C at day 14
Age-specific incidence of severe malaria days
0-28 (patients aged <5 years)
incidence of new clinical episodes of malaria
d15-28
Mean haematocrit at day 28
% of patients experiencing adverse events
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over the first 28 days of follow-up. The follow-up was
extended to three months, and over this time the age-
specific incidence of severe malaria was 2% per month in
the herbal group and 1% per month in the ACT group.
With 95% confidence, the age-specific incidence of severe
malaria in both groups was <6% per month[37].
Stage 4: Isolation and testing of active
compounds
This is the last step of “reverse pharmacology”. A phyto-
medicine can be developed without isolating an active
ingredient, but it is useful to do this for two reasons.
First and foremost there needs to be a phytochemical
marker for quality control and standardization of the
herbal medicine, and also to permit agronomic selection
of the best plants. Secondly it is possible that a new
modern drug could be developed in parallel by the phar-
maceutical industry. However it makes more sense to do
this after the clinical safety and effectiveness have
already been demonstrated, as chances may be higher
that the isolated compound (or a derivative) will also be
safe and effective. Much time and money is wasted in
developing drugs which turn out to be unsafe or ineffec-
tive in humans [38].
Isolating pure active ingredients from a phytomedicine
is not straightforward. Most phytomedicines contain
several compounds with additive or synergistic activities,
or even pro-drugs. Argemone mexicana contains at least
three protoberberine alkaloids in similar amounts
(around 0.5% in the plants from Mali) with similar anti-
malarial activity: berberine, protopine and allocryptopine
(IC50 in vitro = 0.32, 0.32 and 1.46 mcg/ml respectively)
[39]. Whereas all are active in vitro, the absorption of
berberine is poor in some animal models, although it
can be improved by P-glycoprotein inhibitors [40]. It is
not known whether A. mexicana contains any P-glyco-
protein inhibitors, but if it does, their concentration
w o u l da l s ob ei m p o r t a n t .T he pharmacokinetics of
protopine and allocryptopine have not yet been studied
in humans, so it is not known which of these is the best
marker, or whether there is synergy between them (in
which case maybe all should be used as markers). Unlike
berberine, protopine and allocryptopine show a good
selectivity for Plasmodium and their cytotoxicities are
low [39]. Since preliminary in vivo tests using freeze
dried AM decoction were unsuccessful both in mouse
and in rat models (Plasmodium berghei and Plasmodium
chabaudi respectively, unpublished results), the plan is
now to study the in vitro antiplasmodial activity of
plasma samples from healthy volunteers to identify plant
substances or metabolites involved in such activity.
Discussion
While developing new compounds from natural
products could be an important source of new anti-
malarials in the long term, it is also possible to develop
standardized and validated phytomedicines more quickly
and cheaply. The scheme used has already saved consid-
erable time and money in developing a new herbal
anti-malarial in Mali. Since the studied plant is a pan-
tropical weed, results of such a research programme
could be applied in many countries, provided there is
local quality control of the plants.
It is of paramount importance to conduct such
research in an ethical manner, and all the clinical trials
were submitted and approved by an ethics committee.
To be ethical, a non-inferiority trial needs to test a strat-
egy that could be sustained after the end of the research.
During the study there must be proper safeguards in
place to ensure the safety of the patients, so a medical
team was stationed in the village for the whole period to
give immediate care when required. The result was to
inform the villagers which of their traditional remedies
has been clinically shown to be an effective anti-malar-
ial, at what dose, what precautions are necessary in its
preparation, and that they should rapidly seek modern
medical treatment if they do not improve or if danger
Table 5 Oucomes of treatment of uncomplicated malaria by a village health worker with Argemone mexicana
decoction (AM ) or Artemisinin Combination Therapy (ACT ) as first-line anti-malarial (% and 95%CI) [35]
AM group ACT group
No need for 2nd line treatment 89.3% (84.1 – 93.2) 95% (88.8 – 98.3)
T <37.5°C (**) at day 14 93.9 (89.3 - 96.7) 97.0 (91.6 – 99.4)
T <37.5°C at day 28 96.9 (93.5 – 98.9) 99.0 (94.6 – 100.0)
Severe malaria >5yo 0 (0 - 1.83) 0 (0 - 3.62)
Severe malaria (0-5 yo) 1.9% (0.2 – 6.7) 1.9% (0.05 – 10.3)
Severe malaria (all ages) - Coma / convulsions 0 (0 - 1.83) 0 (0 - 3.62)
Adverse effects 14.2% (9.7 - 19.9)* 18.8% (11.7 - 27.8)*
New episode (day 15-28) (parasite positive) 12.8% (8.4 – 18.3) 9.9% (4.9 – 17.5)
*Most common adverse effects : Cough and diarrhoea with AM, vomiting with ACT.
**Temperature in degree Celsius.
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benefit in the long term, and so more ethical, than a
short-term unsustainable intervention. This hypothesis
will be tested in future research on the public health
impact of such information.
With the benefit of hindsight, there are some
improvements which could be made to the scheme. In
the initial selection of the plant, the determining factor
should be the observed treatment-effect correlation in
the RTO rather than the in vitro activity, which can be
misleading. In this case the in vitro activity was largely
attributable to berberine, which is poorly absorbed, and
is probably not (or not directly) responsible for the
activity in humans.
In the dose-escalating study, it would have been better
to start by consulting those familiar with the remedy
about the minimum and maximum doses which patients
can take, to ensure that the traditional healer was pro-
posing his usual range of doses for the study. Based on
this information, two or three different standard dosages
of the phytomedicine could be defined in advance in the
trial protocol. Of course, the same inclusion criteria
must be used throughout the trial, so that the patients
in each group are as similar as possible.
In other contexts the aim of treatment may be differ-
ent. For example in Brazil, Artemisia annua infusion is
being tested as a backup for situations in which the
recommended first-line treatment is not available. These
include stock-outs of standard drugs, and remote areas
which are not reached by the healthcare infrastructure.
Brazil is a low transmission area, and total parasite
clearance is considered mandatory. In this context
ACPR is the chosen outcome measure.
Other phytomedicines for malaria have already been
developed and are government-approved in Burkina
Faso (Cochlospermum planchonii root decoction), in
Ghana (Cryptolepis sanguinolenta root infusion) [41],
and in the Democratic Republic of Congo (Artemisia
annua Anamed leaf infusion). Much of the development
work has already been done on these: their safety has
been demonstrated and they seem efficacious in preli-
minary clinical trials. However further work is needed to
decide how they would fit into public health strategies
for control or elimination of malaria. It is important to
develop cheap and reliable tests for quality control and
standardization of plant material. Larger scale clinical
trials are needed, including children who are most at
risk of severe malaria, if they are intended to be future
users of a validated and officially recommended phyto-
medicine. This is not the case in Mali, where it has
been proposed to test on a small scale a health policy
including Argemone mexicana decoction for the home-
based management of malaria in patients aged over five
years in high transmission areas, thereby saving ACTs
for children aged five years and under [35].
There is a range of other promising anti-malarial phy-
tomedicines which could be developed much faster and
more cheaply than new chemical compounds, because
preliminary work has already provided some information
on their safety and efficacy [42]. Such phytomedicines
could be considered not only for treatment of malaria
but also for prophylaxis and intermittent presumptive
treatment. The proposed methodology could also be
adapted to develop herbal prophylactics, starting from
good ethnomedical observation and progressing though
clinical studies (although the protocols would be differ-
ent from those described here, which are designed to
evaluate potential treatments).
Funding organizations should support the possibility
of developing new types of medicines, including phyto-
medicines, rather than restricting funding only to con-
ventional development of isolated active compounds.
Sustainable public health improvement in remote areas
is a key consideration in such a discussion. Innovative
Public Private Partnerships could also be considered
with companies already expert in the production of
standardized phytomedicines.
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